Novo Nordisk A/S $NVO Stock Holdings Increased by Signaturefd LLC

Signaturefd LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 41.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,831 shares of the company’s stock after acquiring an additional 22,148 shares during the quarter. Signaturefd LLC’s holdings in Novo Nordisk A/S were worth $3,635,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Revolve Wealth Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the period. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. grew its position in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in Novo Nordisk A/S during the 2nd quarter valued at $314,000. 11.54% of the stock is owned by institutional investors and hedge funds.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $46.75 on Friday. The business’s 50-day simple moving average is $47.30 and its 200-day simple moving average is $44.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The firm has a market cap of $208.74 billion, a price-to-earnings ratio of 11.43, a P/E/G ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion during the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 42.79%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NVO shares. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a report on Wednesday. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Four analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.